Department of Radiation Oncology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cancer Res Treat. 2022 Oct;54(4):953-969. doi: 10.4143/crt.2022.329. Epub 2022 Aug 16.
We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method.
Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS).
A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm.
Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT's demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.
我们旨在通过荟萃分析方法研究局部巩固治疗(LCT)的肿瘤疗效和可行性。
检索了 PubMed、MEDLINE、Embase 和 Cochrane 图书馆等四个数据库。目标研究为比较 LCT 组与对照组结果的对照试验。主要终点是总生存期(OS)和无进展生存期(PFS)。
共纳入 54 项研究,涉及 7242 名患者。汇总分析显示,LCT 组的 OS 获益明显,合并优势比为 2.896(95%置信区间[CI],2.377 至 3.528;p<0.001)。关于 PFS,汇总分析显示 LCT 组的合并优势比为 3.045(95%CI,2.356 至 3.937;p<0.001)。在包括具有可靠可比性的研究(例如随机研究或无 LCT 组明显有利预后因素的有意匹配研究)的亚组分析中,LCT 组 OS 的合并优势比为 2.548(95%CI,1.808 至 3.591;p<0.001)。关于 PFS,合并 OR 为 2.656(95%CI,1.713 至 4.120;p<0.001),也有利于 LCT 组。还进行了仅限于随机对照试验(RCT)的亚组分析,OS 和 PFS 的合并优势比分别为 1.535(95%CI,1.082 至 2.177;p=0.016)和 1.668(95%CI,1.187 至 2.344;p=0.003)。与 LCT 相关的≥3 级并发症的发生率大多较低(<10%),与对照组相比并无显著升高。
所有纳入研究的汇总分析结果、具有可靠可比性的选择研究以及 RCT 均表明 LCT 具有生存获益。这些一致的结果表明,LCT 对寡转移患者有益。